Gasdermin D Inhibitor Necrosulfonamide Alleviates Angiotensin II-Induced Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Mice
Open Access
- 19 June 2024
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 14 (6) , 726
Abstract
Abdominal aortic aneurysm (AAA) is a chronic aortic disease that lacks effective pharmacological therapies. This study was performed to determine the influence of treatment with the gasdermin D inhibitor necrosulfonamide on experimental AAAs. AAAs were induced in male apolipoprotein E-deficient mice by subcutaneous angiotensin II infusion (1000 ng/kg body weight/min), with daily administration of necrosulfonamide (5 mg/kg body weight) or vehicle starting 3 days prior to angiotensin II infusion for 30 days. Necrosulfonamide treatment remarkably suppressed AAA enlargement, as indicated by reduced suprarenal maximal external diameter and surface area, and lowered the incidence and reduced the severity of experimental AAAs. Histologically, necrosulfonamide treatment attenuated medial elastin breaks, smooth muscle cell depletion, and aortic wall collagen deposition. Macrophages, CD4+ T cells, CD8+ T cells, and neovessels were reduced in the aneurysmal aortas of necrosulfonamide- as compared to vehicle-treated angiotensin II-infused mice. Atherosclerosis and intimal macrophages were also substantially reduced in suprarenal aortas from angiotensin II-infused mice following necrosulfonamide treatment. Additionally, the levels of serum interleukin-1β and interleukin-18 were significantly lower in necrosulfonamide- than in vehicle-treated mice without affecting body weight gain, lipid levels, or blood pressure. Our findings indicate that necrosulfonamide reduced experimental AAAs by preserving aortic structural integrity as well as reducing mural leukocyte accumulation, neovessel formation, and systemic levels of interleukin-1β and interleukin-18. Thus, pharmacologically inhibiting gasdermin D activity may lead to the establishment of nonsurgical therapies for clinical AAA disease.Keywords
Funding Information
- National Natural Science Foundation of China (81600256, 82001248, 2021-159, Jincaijiao-2020165-Z135050009017)
- Abroad Return Scholar Fund of Shanxi Province (81600256, 82001248, 2021-159, Jincaijiao-2020165-Z135050009017)
- Central Funds Guiding the Local Science and Technology Development (81600256, 82001248, 2021-159, Jincaijiao-2020165-Z135050009017)
This publication has 59 references indexed in Scilit:
- Macrophage-derived GSDMD promotes abdominal aortic aneurysm and aortic smooth muscle cells pyroptosisInternational Immunopharmacology, 2024
- Gasdermin D affects aortic vascular smooth muscle cell pyroptosis and Ang II-induced vascular remodelingHeliyon, 2023
- Gasdermin D Deficiency in Vascular Smooth Muscle Cells Ameliorates Abdominal Aortic Aneurysm Through Reducing Putrescine SynthesisAdvanced Science, 2022
- Disulfiram protects against abdominal aortic aneurysm by ameliorating vascular smooth muscle cells pyroptosisCardiovascular Drugs and Therapy, 2022
- Necrosulfonamide improves post-resuscitation myocardial dysfunction via inhibiting pyroptosis and necroptosis in a rat model of cardiac arrestEuropean Journal of Pharmacology, 2022
- Contemporary Management of Abdominal Aortic AneurysmsCurrent Cardiology Reports, 2022
- Guidelines for the ethical review of laboratory animal welfare People’s Republic of China National Standard GB/T 35892‐2018 [Issued 6 February 2018 Effective from 1 September 2018]Animal Models and Experimental Medicine, 2020
- GSDMD membrane pore is critical for IL-1β release and antagonizing IL-1β by hepatocyte-specific nanobiologics is a promising therapeutics for murine alcoholic steatohepatitisBiomaterials, 2020
- Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 KinaseCell, 2012
- Inhibition of reactive oxygen species attenuates aneurysm formation in a murine modelAtherosclerosis, 2009